ZURA BIO ($ZURA) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.19 per share, missing estimates of -$0.15 by $0.04. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ZURA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ZURA BIO Insider Trading Activity
ZURA BIO insiders have traded $ZURA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ZURA stock by insiders over the last 6 months:
- PARVINDER THIARA sold 1,001,633 shares for an estimated $2,734,458
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ZURA BIO Hedge Fund Activity
We have seen 49 institutional investors add shares of ZURA BIO stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 2,611,532 shares (+12060.8%) to their portfolio in Q4 2024, for an estimated $6,528,830
- ADAR1 CAPITAL MANAGEMENT, LLC removed 1,693,398 shares (-44.9%) from their portfolio in Q4 2024, for an estimated $4,233,495
- STEMPOINT CAPITAL LP removed 1,044,168 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,610,420
- MILLENNIUM MANAGEMENT LLC added 657,420 shares (+1499.0%) to their portfolio in Q4 2024, for an estimated $1,643,550
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 300,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $750,000
- CITADEL ADVISORS LLC removed 279,049 shares (-82.8%) from their portfolio in Q4 2024, for an estimated $697,622
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 259,241 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $648,102
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ZURA BIO Analyst Ratings
Wall Street analysts have issued reports on $ZURA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 04/03/2025
- Oppenheimer issued a "Outperform" rating on 03/26/2025
To track analyst ratings and price targets for ZURA BIO, check out Quiver Quantitative's $ZURA forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
